SPECTRUM: Early global real-world results with aflibercept 8 mg in patients with previously treated neovascular age-related macular degeneration

Louise Downey,[1] Clare Bailey,[2] Clemens Lange,[3,4] Varun Chaudhary,[5] Paolo Lanzetta,[6,7] Hassiba Oubraham,[8] Martin Kirchner,[9] Tobias Machewitz,[10] Helmut Allmeier,[11] Xin Zhang,[11] Zoran Hasanbasic,[11] Marion R. Munk,[12,13,14]
on behalf of the SPECTRUM study investigators

[1]Hull and East Yorkshire NHS Trust, UK; [2]Department of Ophthalmology, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK; [3]Eye Center, Faculty of Medicine, Albert-Ludwig University Freiburg, Freiburg, Germany; [4]Department of Ophthalmology, St Franziskus Hospital, Münster, Germany; [5]Hamilton Regional Eye Institute, St Joseph's Healthcare Hamilton, McMaster University, Hamilton, ON, Canada; [6]Department of Medicine–Ophthalmology, University of Udine, Udine, Italy; [7]Istituto Europeo di Microchirurgia Oculare (IEMO), Udine, Milan, Italy; [8]Centre OPHTA-45, Montargis, France; [9]Bayer AG, Leverkusen, Germany; [10]Bayer AG, Berlin, Germany; [11]Bayer Consumer Care AG, Basel, Switzerland; [12]Augenarzt Praxisgemeinschaft Gutblick AG, Pfäffikon, Switzerland; [13]Department of Ophthalmology, University Hospital Bern, Bern, Switzerland; [14]Northwestern University, Feinberg School of Medicine, Chicago, IL, USA

Presented at the American Society of Retina Specialists 43rd Annual Meeting 2025, Long Beach, CA, USA, July 30 – August 2, 2025

Disclosures

- **Louise Downey:** Honoraria from AbbVie, Alimera Sciences, Bayer, Novartis, and Roche; and has served on advisory boards for AbbVie, Alimera, Bayer, Biogen, Novartis, and Roche**.**
- **CB:** Received honoraria from Alimera Sciences, Apellis, Bayer, and Roche; and has served on advisory boards for Apellis, Bayer, Boehringer Ingelheim, Janssen, and Roche **CL:** Receives honoraria from Apellis, Bayer, Biogen, and Novartis. **VC:** Consulting fees from EyePoint; receives grants from Bayer, Novartis, Roche; and serves on advisory boards for Alcon, Apellis, Bayer, Boehringer Ingelheim, Novartis, and Roche. **PL:** Consultant for Aerie Pharmaceuticals, Allergan, Annexon, Apellis, Bausch + Lomb, Bayer, Biogen, Boehringer Ingelheim, Eyepoint, Genentech, I-Care, Novartis, Ocular Therapeutix, Outlook Therapeutics, and Roche. **HO:** Consultant for AbbVie, Bayer, Novartis, and Roche. **MK** and **TM**: Employees of Bayer AG. **HA**, **XZ**, and **ZH**: Employees of Bayer Consumer Care AG. **MRM**: Consulting fees from AbbVie, Allergan, Apellis, Aviceda Therapeutics, Bayer, Boehringer Ingelheim, Dandelion, EyePoint, Gensight, Isarna Therapeutics, Iveric Bio, Kubota, Lumithera, Novartis, Ocuterra, Oculis, Ocular Therapeutix, RetinAI, Roche, and Zeiss
- The SPECTRUM study (NCT06075147) was sponsored by Bayer Consumer Care AG, Basel, Switzerland
- The sponsor participated in the design and conduct of the study, analysis of the data, and preparation of this presentation
- Medical writing support, under the direction of the authors, was provided by ApotheCom and funded by Bayer Consumer Care AG (Basel, Switzerland), in accordance with Good Publication Practice (GPP) guidance (*Ann Intern Med*. 2022;175:1298–1304)
- Data originally presented at ARVO 2025, Salt Lake City, UT, USA, May 4–8, 2025

SPECTRUM: Global real-world study of aflibercept 8 mg

A **24-month, non-interventional country** and **global cohort** study planned in **18 countries**

2 indications, 4 patient cohorts

Treatment-naïve **nAMD** and previously treated **nAMD**
Treatment-naïve **DME** and previously treated **DME**

Primary endpoint: Change in **VA** from **BL to Month 12**

Secondary endpoints include:

- Change in **VA** and **CRT** from BL to Month 6
- Number of **injections, visits**, and **safety** from BL to Month 6

To date, **2896** patients enrolled

Australia, Canada, Denmark, Finland, France, Germany, Italy, Japan, Republic of Korea, The Netherlands, Norway, Portugal, Saudi Arabia, Spain, Sweden, Switzerland, United Arab Emirates, United Kingdom

BL, baseline; CRT, central retinal thickness; DME, diabetic macular edema; nAMD, neovascular age-related macular degeneration; VA, visual acuity.

SPECTRUM inclusion criteria

	Population	Diagnosis	Treatment
nAMD cohorts	Aged ≥50 years	A diagnosis of nAMD	Patients across all cohorts had to have been prescribed aflibercept 8 mg as part of routine clinical practice
DME cohorts	Aged ≥18 years with type 1 or type 2 diabetes mellitus	A diagnosis of DME	

All patients were categorized as being either:

Treatment-naïve
Never been exposed to any medical treatment for nAMD/DME

Previously treated
Received prior treatment, including other anti-VEGFs, up to prespecified timepoints before study start

Anti-VEGF, anti-vascular endothelial growth factor.

Enrollment overview

To date, **979** out of **1110 (88%)** planned patients have been enrolled in the **previously treated nAMD** cohort (as of May 30, 2025)



Early outcomes in the first ~100 patients with previously treated nAMD who had a visit and VA assessment at Week 4

Baseline characteristics: Previously treated nAMD

Analysis of patients with a VA assessment at Week 4[a]

Total: 110 patients

Mean age: 80.2 ± 8.1 years

Median (min, max) time from nAMD diagnosis: 31.5 (1.3, 178.7) months

Mean baseline VA: 62.6 ± 19.3 ETDRS letters

Mean baseline CRT: 321 ± 102 µm

Previous nAMD medication



Sex



Race[b]



FAS. Percentages may not add up to 100 due to rounding.

[a]Data are mean ± SD unless otherwise indicated. [b]Data on race were collected for Australia, Canada, Germany, Italy, Japan, Portugal, South Korea, Saudi Arabia, Spain, Switzerland, United Arab Emirates, and the UK only.
ETDRS, Early Treatment Diabetic Retinopathy Study; FAS, full analysis set; Max, maximum; Min, minimum; SD, standard deviation; UK, United Kingdom.

Key endpoint: VA through Week 4





FAS, OC. Values have been rounded to the nearest decimal point. Error bars are 95% CI.
CI, confidence interval; OC, observed cases.

CRT through Week 4





FAS, OC. Values have been rounded to the nearest decimal point. Error bars are 95% CI.

Proportion of patients without fluid through Week 4



FAS, OC. Values have been rounded to the nearest decimal point. Based on instructions in the case report form, fluid data were collected during a macular assessment (6 mm) per investigator discretion.

Safety overview: Adverse events

Ocular safety in the study eye	Total (N=110)
Ocular TEAEs, n (%)	6 (5.5)
Serious ocular TEAEs, n (%)	1 (0.9)

No non-ocular TEAEs were reported

Data are from the SAF.
SAF, safety analysis set; TEAE, treatment-emergent adverse event.

Early outcomes in the first ~100 patients with previously treated nAMD who had a visit and VA assessment at Week 8

Baseline characteristics: Previously treated nAMD

Analysis of patients with a VA assessment at Week 8[a]

Total: 104 patients

Mean age: 79.5 ± 7.3 years

Median (min, max) time from nAMD diagnosis: 36.9 (1.4, 178.9) months

Mean baseline VA: 61.6 ± 19.4 ETDRS letters

Mean baseline CRT: 316 ± 102 µm

Previous nAMD medication



Race[b]



Sex



FAS. Percentages may not add up to 100 due to rounding.

[a]Data are mean ± SD unless otherwise indicated. [b]Data on race were collected for Australia, Canada, Germany, Italy, Japan, Portugal, South Korea, Saudi Arabia, Spain, Switzerland, United Arab Emirates, and the UK only.

Key endpoint: VA through Week 8





FAS, OC. Values have been rounded to the nearest decimal point. Error bars are 95% CI.

CRT through Week 8





FAS, OC. Values have been rounded to the nearest decimal point. Error bars are 95% CI.

Proportion of patients without fluid through Week 8



FAS, OC. Values have been rounded to the nearest decimal point. Based on instructions in the case report form, fluid data were collected during a macular assessment (6 mm) per investigator discretion.

Safety overview: Adverse events

Ocular safety in the study eye	Total (N=104)
Ocular TEAEs, n (%)	4 (3.9)
Serious ocular TEAEs, n (%)	0

No non-ocular TEAEs were reported

Data are from the SAF.

Early findings from SPECTRUM support the real-world effectiveness and safety of aflibercept 8 mg in the treatment of previously treated nAMD

More than **2800** patients enrolled in SPECTRUM across **17 countries** to date

More than **900** patients enrolled in the **previously treated nAMD cohort** across **13 countries** to date

Early clinical outcomes at Week 4/Week 8

- Stable VA and reduced CRT following switch to aflibercept 8 mg

Safety outcomes at Week 4/Week 8

- No new safety signals identified

As the **first global real-world study of aflibercept 8 mg**, early findings from SPECTRUM will help **inform clinical management** of previously treated nAMD in patients receiving aflibercept 8 mg

Month 6 data will be presented in **2025,** with Month 12 and Month 24 analyses on track